An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
about
Emerging preclinical pharmacological targets for Parkinson's diseaseDisease-modifying therapeutic directions for Lewy-Body dementiasSynthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseGeneration of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug ScreeningPuromycin-resistant lentiviral control shRNA vector, pLKO.1 induces unexpected cellular differentiation of P19 embryonic stem cells.Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease modelViral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioningInhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease ModelTherapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.Recent advances in RNA interference therapeutics for CNS diseases.Gene therapy for misfolding protein diseases of the central nervous system.Up-regulation of SNCA gene expression: implications to synucleinopathiesStudies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference.Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines.Gene-based therapies in Parkinson's disease.Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsRNA Interference of Human α-Synuclein in Mouse.Antioxidant gene therapy against neuronal cell death.Recombinant AAV as a platform for translating the therapeutic potential of RNA interference.Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?Lentiviral vector-mediated RNA silencing in the central nervous system.Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.Tristetraprolin inhibits mitochondrial function through suppression of α-Synuclein expression in cancer cells.Gene therapy targeting mitochondrial pathway in Parkinson's disease.The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression.Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.shRNA-induced saturation of the microRNA pathway in the rat brain.Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.Down-regulating α-synuclein for treating synucleopathies.Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.
P2860
Q26764724-24F16109-DD4B-43A7-83B2-FC921268FD7FQ26782907-561895F7-5E18-4677-8493-BD0D42C058D4Q26830610-00339DA5-5818-4456-927A-E8F2BA0516F2Q26851517-33DA76FA-BA3E-4099-A7A8-13E54C91DAEAQ28068464-7B3AC606-1BFC-48E7-BC95-C3D8A8510FCFQ28547585-2FD57085-B0E8-47D3-91ED-1B21F6CECB0FQ33772540-F3CCC31E-57D7-428E-BE92-64D96B707461Q35054395-CDE97345-F230-42D7-B3F8-6519262EDBB9Q35156007-842FA28C-6521-455E-9151-693AFEF93031Q36040166-0539EF2B-4E69-42B1-9AA8-CF88D7271F5CQ36055122-43A791A1-A492-42B7-8826-D4D84BD25840Q36237308-E7D0DBFC-1301-43B7-BC35-77F6B28D6C35Q36543516-16ABCF88-45E9-42C8-AC60-BDA912A5E3F5Q36983193-8BBF3B9A-3FCD-44FA-9602-860D3FE2AC81Q36983203-A97BC51A-D253-4E55-BA1D-C8DE5D473A88Q37004246-F15B38D3-7D42-401C-9378-07B55B37A42EQ37105696-6BC81EFF-4A9E-4233-B7B9-AE450F49FE3FQ37327641-4CADEA75-D70A-42F2-8682-E763CCC9D4B2Q37506503-D3235CBD-ACBC-4216-9C65-6467B8EE0817Q37516424-379E9B31-668E-4C53-86CD-CF193C0CD08AQ37566684-C4388BEA-591E-45EB-9228-81198BADE670Q37614503-7BCB888F-F0EC-4BBD-A530-B01763D94CEAQ37647941-AB845889-0727-47F7-9858-62BEF602A2C1Q37696045-C357D5D6-56D9-4940-A578-96A0E54BBCDFQ38128456-0009A171-9C3A-4887-A13D-FCB75ECBF8ABQ38148784-2F85572D-BCE1-4F6C-BDF6-86D9F8B67BC0Q38463583-7B2F821D-813E-4B37-A8D1-4F06E2C4C37EQ38541943-4495579E-F383-45ED-89B7-D9E6B8B99933Q38607819-E9D2F984-F332-4CA1-8EDE-533CAAE254E1Q38772195-A29E4B3E-8653-4E2F-991E-777D6F6A238AQ38823785-A67A4F70-6444-4F44-BFC5-67D1D2D8D7B0Q38836746-6468B9E2-AA43-49FB-8A10-FD42E30FBB60Q38957332-5666AA9C-B4C8-4095-A8F9-076298A50BFDQ39693289-E29A53C7-92E9-4201-A814-FB7A28ABA389Q42179493-1674A5A4-0426-4358-B3B0-65A1A518AC03Q42245600-7F265C19-139C-4F28-B143-7AA2A5321E51Q47130088-6A2B4BBC-897A-4B60-B7C4-E329B8190D02Q47259722-D8993E56-7F6E-46E6-8BFF-FBD6CB55F81DQ48548334-6DE3E97A-6D10-4C56-83E3-33B98F5783EDQ50335089-6D940527-3239-4352-AEFE-B7D11C4DBD41
P2860
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
An α-synuclein AAV gene silenc ...... toxicity in dopamine neurons.
@en
type
label
An α-synuclein AAV gene silenc ...... toxicity in dopamine neurons.
@en
prefLabel
An α-synuclein AAV gene silenc ...... toxicity in dopamine neurons.
@en
P2093
P2860
P921
P1433
P1476
An α-synuclein AAV gene silenc ...... toxicity in dopamine neurons.
@en
P2093
Adrian P Kells
Christina E Khodr
Jyothi Pedapati
Krystof S Bankiewicz
Martha C Bohn
Mohan K Sapru
Neva C West
P2860
P304
P356
10.1016/J.BRAINRES.2011.04.036
P577
2011-04-22T00:00:00Z